Author(s): Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, et al.
Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the treatment of and prophylaxis against influenza. In this paper, the new potent NA inhibitor R-125489 is reported for the first time. R-125489 inhibited the NA activities of various type A and B influenza viruses, including subtypes N1 to N9 and oseltamivir-resistant viruses. The survival effect of R-125489 was shown to be similar to that of zanamivir when administered intranasally in a mouse influenza virus A/Puerto Rico/8/34 infection model. Moreover, we found that the esterified form of R-125489 showed improved efficacy compared to R-125489 and zanamivir, depending on the acyl chain length, and that 3-(O)-octanoyl R-125489 (CS-8958) was the best compound in terms of its life-prolonging effect (P < 0.0001, compared to zanamivir) in the same infection model. A prolonged survival effect was observed after a single administration of CS-8958, even if it was given 7 days before infection. It is suggested that intranasally administered CS-8958 works as a long-acting NA inhibitor and shows in vivo efficacy as a result of a single intranasal administration.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/18955520
Author(s): Smee D, Huffman JH, Morrison AC, Barnard DL, Sidwell RW
Author(s): Nakayama M, Suzuki K, Toda M, Okubo S, Hara Y, et al.
Author(s): Nakayama M, Toda M, Okubo S, Hara Y, Shimamura T
Author(s): Mori S, Miyake S, Kobe T, Nakaya T, Fuller SD, et al.
Author(s): Kaihatsu K, Mori S, Matsumura H, Daidoji T, Kawakami C, et al.
Author(s): Sundararajan A, Ganapathy R, Huan L, Dunlap JR, Webby RJ, et al.
Author(s): Sekizawa H, Ikuta K, Mizuta K, Takechi S, Suzutani T
Author(s): Sokmen M, Angelova M, Krumova E, Pashova S, Ivancheva S, et al.
Author(s): Gaush CR, Smith TF
Author(s): Davis J, Murphy EA, McClellan JL, Carmichael MD, Gangemi JD
Author(s): Gazák R, Purchartová K, Marhol P, Zivná L, Sedmera P, et al.